BDTOFA XR Tablets

BDTOFA XR 11 mg is a prescription medicine containing Tofacitinib Extended-Release 11 mg. The pack shown contains 1 × 10 tablets. Tofacitinib is a Janus kinase (JAK) inhibitor used under medical supervision for certain inflammatory and autoimmune conditions. Indian regulatory information lists the 11 mg extended-release strength for moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and moderately to severely active ulcerative colitis in appropriate adult patients who have an inadequate response or intolerance to specified prior treatments. 

BDTOFA XR 11 mg contains Tofacitinib citrate equivalent to Tofacitinib 11 mg in an extended-release tablet formulation. The extended-release formulation is designed to provide the medicine over an extended period and is generally taken according to the prescribing doctor's instructions. The 11 mg XR strength can be used as an extended-release regimen in patients for whom tofacitinib therapy is appropriate.

Tofacitinib works by inhibiting Janus kinase (JAK) enzymes, which are involved in signalling pathways associated with inflammation and immune-system activity. By reducing these signals, it can help control disease activity in conditions such as rheumatoid arthritis, psoriatic arthritis and ulcerative colitis when prescribed for the appropriate patient.

BDTOFA XR 11 mg is a prescription-only medicine. It should be used only under the supervision of a qualified doctor. Tofacitinib has important safety warnings, including risks involving serious infections, blood clots and cardiovascular events in certain patients; therefore, the patient's medical history and ongoing treatment should be considered by the prescribing physician.